Payer/Hta Requirements In Metastatic Breast Cancer.

INTRODUCTION • Triple-negative breast cancer (TNBC) represents 10%–20% of invasive breast cancers1 and has a very poor prognosis.2 There is a particular unmet need in TNBC, with a lack of clinically established targeted therapies3; chemotherapy is the only option for metastatic TNBC.4 • To facilitate access to new treatments, it is increasingly important to understand payer evidence needs in addition to regulatory evidence requirements.5 • Traditionally, payers focus on hard endpoints such as overall survival (OS), and recommendations for reimbursement would ideally be supported by statistically significant improvement in OS. However, this is sometimes difficult due to long follow-up durations and post-study treatment.